A provider's guide to helping patients save on Revumenib (Revuforj). Learn about copay programs, patient assistance, and cost conversation strategies.
As a prescriber, you know that the most effective medication is the one your patient actually takes. For Revumenib (brand name Revuforj), cost can be a significant barrier to adherence — and in the context of relapsed or refractory acute leukemia, treatment gaps can have serious consequences.
Revumenib carries a wholesale acquisition cost of approximately $39,500 per month, or roughly $474,000 per year. While most patients do not pay the full list price, even modest cost-sharing on a specialty oncology drug can create financial strain that leads to delayed fills, dose skipping, or outright abandonment of therapy.
This guide provides a practical overview of the savings programs, financial assistance options, and workflow strategies you can use to help your patients access Revumenib without the financial burden derailing their treatment.
The out-of-pocket cost for Revumenib varies widely depending on the patient's insurance situation:
Understanding your patient's insurance landscape is the first step toward connecting them with the right program.
Syndax Pharmaceuticals offers a copay assistance program through their SyndAccess patient support platform. Key details:
For commercially insured patients, this should be the first resource you explore. Enrollment can often be completed during the prior authorization process.
Beyond copay assistance, SyndAccess offers a broader support platform that includes:
As a provider, you can refer patients to SyndAccess proactively. Many practices integrate SyndAccess enrollment into their standard workflow for Revumenib prescriptions.
For most specialty oncology drugs at this price point, traditional coupon card platforms like GoodRx, SingleCare, or RxSaver have limited utility. Revumenib is dispensed exclusively through specialty pharmacies, and the pricing dynamics of specialty distribution differ significantly from retail pharmacy.
That said, it is worth checking these platforms in case discounted pricing is available:
In most cases, the manufacturer's copay program through SyndAccess will provide better savings than third-party coupon platforms for this medication.
For patients who are excluded from the commercial copay program (Medicare, Medicaid, uninsured), additional resources include:
As of 2026, there is no generic version of Revumenib available. Given its recent FDA approval (November 2024), generic competition is unlikely for several years.
From a therapeutic standpoint, Revumenib occupies a unique niche as the only FDA-approved menin inhibitor. There is no direct therapeutic equivalent available for substitution. However, several other menin inhibitors are in clinical development:
For patients who cannot access Revumenib due to cost, clinical trial enrollment for one of these investigational menin inhibitors may be an alternative pathway. See alternatives to Revumenib for more information.
For patients with KMT2A-rearranged leukemia who cannot access any menin inhibitor, treatment decisions should be guided by the clinical context and may include intensive chemotherapy regimens, venetoclax-based combinations, or consideration of hematopoietic stem cell transplantation.
Cost conversations should not be an afterthought. For a drug like Revumenib, proactive financial planning can prevent treatment delays and improve adherence. Here are practical strategies:
When you determine that Revumenib is appropriate, mention the cost landscape during the treatment discussion — before the prescription is written. A brief statement like "This medication is expensive, but there are programs that can bring your cost to zero" sets the right expectations.
Train your clinical coordinators or pharmacy liaisons to contact SyndAccess (1-888-567-SYND) as a standard step in the Revumenib prescribing process. Many practices assign a specific staff member to handle specialty pharmacy coordination for oncology drugs.
Use validated screening tools (such as the COST measure/FACIT-COST) or simple questions to identify patients at risk for financial toxicity. Patients may not volunteer cost concerns unprompted.
Note which programs the patient has been enrolled in, copay amounts, and renewal dates. This helps the entire care team stay informed and prevents lapses in coverage.
Build relationships with the specialty pharmacies that dispense Revumenib. When issues arise — stock delays, insurance denials, cost surprises — having a direct contact speeds resolution. Use Medfinder for Providers to help locate pharmacy availability.
Patients who change insurance plans (employer switch, aging into Medicare, loss of coverage) are at high risk for treatment interruption. Flag these transitions in advance and re-evaluate financial assistance eligibility.
The cost of Revumenib is substantial, but the financial assistance landscape for this drug is relatively robust — especially for commercially insured patients. By integrating cost conversations and SyndAccess enrollment into your standard prescribing workflow, you can significantly reduce the likelihood that financial barriers will compromise your patient's treatment outcomes.
For provider-specific tools and resources, visit Medfinder for Providers. For patient-facing cost information, share our guide on how to save money on Revumenib with your patients.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
